3 completed, 2 active not recruiting, 2 not yet recruiting, 2 unknown. 5 Phase 2, 3 Not applicable, 2 Phase 3, 1 Phase 1.
Follow Orygen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisdexamfetamine For the Treatment of Conduct Disorder in Children Lidexamfetamine - Conduct Disorder | Phase 2 | Not yet recruiting | Orygen | 30 | 2027-02-01 | 2026-11-06 |
| Virtual Reality for Vocational Recovery Virtual reality for vocational recovery - Mental Health Disorder | Not applicable | Not yet recruiting | Orygen | 20 | 2025-08-01 | 2025-08-11 |
| Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety Third wave VR therapy - Depression Anxiety Disorder | Phase 2 | Active not recruiting | Orygen | 75 | 2025-04-01 | 2026-09-14 |
| Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) - Avoidant/Restrictive Food Intake Disorder (ARFID) | Not applicable | Completed | Orygen | 3 | 2024-06-27 | 2026-06-30 |
| Chatsafe Netherlands: Improving Safe Suicide Communication for Young People on Social Media Social Media campaign - Suicide Prevention, Communication | Not applicable | Unknown | 113 Suicide Prevention | 400 | 2024-04-08 | 2024-05-01 |
| Guanfacine Extended-release for Adolescents With Cannabis Use Guanfacine Extended Release Oral Tablet, Residential withdrawal, Engagement with alcohol and other drug services - Cannabis Use Disorder | Phase 2 | Recruiting | Orygen | 100 | 2023-07-27 | 2025-07-31 |
| AMP SCZ® Observational Study: PREDICT-DPACC Clinical High Risk, Psychosis | Active not recruiting | Brigham and Women's Hospital | 2617 | 2022-06-02 | 2025-10-31 | |
| The Staged Treatment in Early Psychosis Study Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine - Psychotic Disorders, Personality Disorders | Phase 3 | Completed | Orygen | 342 | 2016-04-01 | 2025-10-02 |
| Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 80 | 2014-06-01 | 2014-02-25 |
| Promotion of Self-help Strategies for Depression Mood Memo emails - Depressive Disorder, Depression | Phase 1 / Phase 2 | Completed | Orygen | 1736 | 2011-11-01 | 2013-12-11 |
Psychotic Disorders (3) · Depression (2) · 22q11 Deletion Syndrome (1) · Aggression (1) · Anxiety Disorders (1) · Avoidant Restrictive Food Intake Disorder (1) · Communication (1) · Conduct Disorder (1) · Depressive Disorder (1) · Feeding and Eating Disorders (1) · Mental Disorders (1) · Personality Disorders (1) · Psychological Well-Being (1) · Suicidal Ideation (1) · Suicide Prevention (1)
Cognitive Behavioral Therapy (1) · Ethanol (1) · Fish Oils (1) · Fluoxetine (1) · Guanfacine (1) · Palliative Care (1) · Standard of Care (1)
Australia (7) · Canada (1) · Chile (1) · China (1) · Denmark (1) · Germany (1) · Holy See (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Alexandre A Guerin, PhD (1) · Andrea Phillipou (1) · Andrew J Mackinnon, PhD (1) · Anthony F Jorm, PhD, DSc (1) · Barnaby Nelson, Ph.D. (1) · Jennifer Nicholas, PhD (1) · Marco Armando, MD, PhD (1) · Martha E Shenton, Ph.D. (1) · Patrick McGorry, MD, PhD (1) · Scott Woods, M.D. (1)
PMID 23805231, PMID 37378974, PMID 39566719, PMID 42728096, PMID 42805768
U01MH105258 (1), U01MH124631 (1), U01MH124639 (1), U24MH124629 (1)